Tagged with innovation,

family business Adrian Fernandez, current CEO, shares his experience of taking a domestic company international and the viability of the family business model in the contemporary market.   As a rapidly internationalizing company, how much of a burden have regulatory barriers between countries placed on your business? Its not too much of…

medtech Margarita Alfonsel, general secretary of the Spanish Federation of Healthcare Technology Companies (FENIN), discusses the state of the medtech sector in Spain today, outlining the industry’s biggest priorities and areas of improvement.   The medical technology industry in Spain has a market size of EUR 6.8 million. As General Secretary…

innovation Javier Anitua, Managing Director of Mylan Spain, discusses the preservation of Spain’s pharmacy model, preventive solutions for pharmacists, and the need for higher generic penetration in Spain.   What more needs to be done in Spain to communicate the value that generics bring to stakeholders who set prices? The sustainability…

science Maria Luisa Poncela has been the General Secretary of Science, Technology and Innovation under the Spanish Ministry of Economy since January 2012. In her role she fosters business competitiveness and technology transfer across different sectors and regions, and in an exclusive interview with PharmaBoardroom she outlines some of the key…

biotech For many years, Spain’s biotechnology sector was lagging behind the powerhouses of countries like the US and UK. Today, the sector touts a significantly different story, due to strategic investments by Spain’s government. Regina Revilla, president of Spain’s biotech association ASEBIO, details the history of biotech in Spain and outlines…

Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…

UAE Jan Van der Goten, GCC Managing Director of Janssen UAE, talks about his experience at Janssen GCC as regional manager, how collaboration with other companies in the industry will bring about better results for the issue of diabetes, and why this may be harder to accomplish than expected.   You…

UAE Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late.   Our approach to…

Collaboration Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late. What are some of…

Collaboration Paolo Carli, Head of Middle East, KSA & Egypt for Merck Serono, speaks about the regions most pressing health issues—hypertension and diabetes— and how he thinks that collaboration of the industry with the government and educational institutes will help overcome this problem before it’s too late. What are some of…

UAE Walid Kattouha, Head of the Middle East Cluster of Novartis, speaks about why local knowledge is key to the company’s success, what have been and continues to be the major challenges for the company, and what the future looks like.   You are the leading pharmaceutical company in the Middle…

MNCs Lloyd D. Balajadia, Executive Director of Lloyd Laboratories talks about the advantages and disadvantages of the recent spike in generic medicine within the Philippine market, why despite a contract manufacturer being good for Lloyd Laboratories, it would be but bad for the job market and business opportunities in the Philippines,…